This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Thermo Fisher Scientific is a scientific instrument maker and a world leader in serving science. In Nov 2006, Thermo Fisher Scientific, Inc. was formed through the merger of Thermo Electron Corporation with Fisher Scientific International Inc. On Feb 3, 2014, Thermo Fisher acquired Life Technologies Corporation. Following the acquisition, the new reporting segments are: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Thermo Fisher Scientific (TMO) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Thermo Fisher (TMO) delivered earnings and revenue surprises of 2.87% and 1.31%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Edwards Lifesciences (EW) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Edwards Lifesciences (EW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Thermo Fisher Stock Worth Holding on to in Your Portfolio?
by Zacks Equity Research
TMO continues to capture investors' attention due to its innovative product launches and trusted partnership status.
Thermo Fisher Scientific (TMO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Thermo Fisher (TMO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Robust Analytical Instruments Segment Likely to Aid TMO's Q4 Earnings
by Zacks Equity Research
Strength in Analytical Instruments and Specialty Diagnostics segments is likely to have driven Thermo Fisher's fourth-quarter 2024 performance.
ISRG Likely to Beat Q4 Expectations: How to Play the Stock?
by Indrajit Bandyopadhyay
Intuitive Surgical's fourth-quarter results are likely to reflect solid performance in the company's Instruments & Accessories segment. Improving margins buoy optimism.
Will Thermo Fisher (TMO) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Thermo Fisher (TMO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Macroeconomic Woes, Competition Weigh on TMO's Stock Performance
by Zacks Equity Research
The industry-wide trend of difficult macroeconomic conditions is creating a challenging business environment for Thermo Fisher.
IQVIA (IQV) Surges 3.0%: Is This an Indication of Further Gains?
by Zacks Equity Research
IQVIA (IQV) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Bioproduction Prospects to Drive TMO Shares Despite Macroeconomic Woes
by Zacks Equity Research
TMO's recent strategic acquisitions, including the $3.1-billion acquisition of Olink Holdings, are likely to drive future growth.
The Zacks Analyst Blog Highlights Visa, Linde, Thermo Fisher Scientific, Tile Shop and Autoscope
by Zacks Equity Research
Visa, Linde, Thermo Fisher Scientific, Tile Shop and Autoscope are included in this Analyst Blog.
Top Analyst Reports for Visa, Linde & Thermo Fisher Scientific
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Visa Inc. (V), Linde plc (LIN) and Thermo Fisher Scientific Inc. (TMO), as well as two micro-cap stocks Tile Shop Holdings, Inc. (TTSH) and Autoscope Technologies Corporation (AATC).
TMO Institutional & Insider Stock Sell-Offs Upset Market: How to Play
by Urmimala Biswas
Investors are also concerned about Thermo Fisher's continuous decline in testing revenues due to the decline in COVID testing-related demand.
Should You Continue to Hold TMO Stock in Your Portfolio?
by Zacks Equity Research
Investors continue to be optimistic about Thermo Fisher due to its strategic acquisitions and string of product launches.
Strength Seen in AngioDynamics (ANGO): Can Its 23.3% Jump Turn into More Strength?
by Zacks Equity Research
AngioDynamics (ANGO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
TMO Stock to Gain From the New Additions to CTS Portfolio of Products
by Zacks Equity Research
Thermo Fisher launches CTS Detachable Dynabeads CD4 and CTS Detachable Dynabeads CD8 to enhance cell therapy development and production.
Thermo Fisher (TMO) Down 7.4% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Thermo Fisher (TMO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
End Market Growth, New Acquisitions Drive Thermo Fisher's Shares
by Zacks Equity Research
A few of its recent strategic acquisitions that are likely to drive future growth for TMO include the $3.1-billion acquisition of Olink Holdings.
The Zacks Analyst Blog Highlights Thermo Fisher Scientific, NextEra Energy and Lowe's
by Zacks Equity Research
Thermo Fisher Scientific, NextEra Energy and Lowe's are included in this Analyst Blog.
Top Analyst Reports for Thermo Fisher, NextEra Energy & Lowe's
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Thermo Fisher Scientific Inc. (TMO), NextEra Energy, Inc. (NEE) and Lowe's Companies, Inc. (LOW).
Why Thermo Fisher (TMO) International Revenue Trends Deserve Your Attention
by Zacks Equity Research
Explore how Thermo Fisher's (TMO) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
The Zacks Analyst Blog Meta, Tesla, Thermo Fisher Scientific and Food Comes From
by Zacks Equity Research
Meta, Tesla, Thermo Fisher Scientific and Food Comes From are included in this Analyst Blog.
Top Analyst Reports for Meta Platforms, Tesla & Thermo Fisher Scientific
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Meta Platforms, Inc. (META), Tesla, Inc. (TSLA) and Thermo Fisher Scientific Inc. (TMO), as well as a micro-cap stock Where Food Comes From, Inc. (WFCF).
Thermo Fisher (TMO) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for Thermo Fisher (TMO) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.